Table 1 Clinical and Demographic Characteristics of Patients with CSDH
Variables | All patients (N = 653) | Recurrence(n = 96) | Non-Recurrence(n = 557) | P-value |
|---|---|---|---|---|
Postoperative BUN (mmol/L) | 4.9 (4,6.4) | 5.9 (4.4,6.9) | 4.9 (3.9,6.3) | < 0.001 |
Demographic parameters | ||||
Age (years) | 72 (64,80) | 75 (69,82) | 71 (63,80) | 0.012 |
Gender | 0.263 | |||
Male, n (%) | 561 (85.9%) | 86 (89.6%) | 475 (85.3%) | |
Female, n (%) | 92 (14.1%) | 10 (10.4%) | 82 (14.7%) | |
Current drinking, n (%) | 234 (35.8%) | 34 (35.4%) | 200 (35.9%) | 0.926 |
Current smoking, n (%) | 237 (36.3%) | 33 (34.4%) | 204 (36.6%) | 0.672 |
Baseline SBP (mmHg) | 138 (126,153) | 135 (124,151) | 140 (127,153) | 0.122 |
Baseline DBP (mmHg) | 79 (71,87) | 77 (71,84) | 79 (71,87) | 0.091 |
Laboratory investigation | ||||
Blood glucose (mmol/L) | 5.5 (4.7,6.6) | 5.7 (5,6.7) | 5.4 (4.7,6.6) | 0.265 |
Cr (μmol/L) | 67 (58,77) | 68 (60,80) | 66 (57,77) | 0.097 |
Leukocyte (X10^9/L) | 6.94 (5.81,8.43) | 6.51 (5.52,7.55) | 7.01 (5.85,8.62) | 0.010 |
Neutrophil (X10^9/L) | 4.62 (3.68,6.15) | 4.30 (3.51,5.31) | 4.70 (3.71,6.26) | 0.012 |
Lymphocyte (X10^9/L) | 1.46 (1.10,1.81) | 1.46 (1.17,1.83) | 1.47 (1.1,1.81) | 0.650 |
Erythrocyte (X10^12/L) | 4.23 ± 0.51 | 4.19 ± 0.52 | 4.24 ± 0.51 | 0.379 |
Hemoglobin (g/L) | 132 (120,142) | 132 (119,142) | 132 (119,140) | 0.442 |
Platelet (X10^9/L) | 211 (172,249) | 194 (164,239) | 213 (175,251) | 0.010 |
Prothrombin Time(s) | 13.3 (12.8,13.9) | 13.4 (12.8,14.0) | 13.3 (12.8,13.9) | 0.642 |
INR | 1.02 (0.97,1.08) | 1.02 (0.98,1.10) | 1.02 (0.97,1.07) | 0.719 |
Fibrinogen (g/L) | 3.61 (3.09,4.28) | 3.50 (2.89,4.15) | 3.64 (3.15,4.30) | 0.046 |
Comorbidities | ||||
Hypertension, n (%) | 252 (38.6%) | 40 (41.7%) | 212 (38.1%) | 0.503 |
Diabetes mellitus, n (%) | 77 (11.8%) | 11 (11.5%) | 66 (11.8%) | 0.913 |
Cardiovascular disease, n (%) | 42 (6.4%) | 6 (6.3%) | 36 (6.5%) | 0.937 |
Medication use | ||||
Atorvastatin therapy, n (%) | 478 (73.2%) | 74 (77.1%) | 404 (72.5%) | 0.352 |
PAMBA therapy, n (%) | 189 (28.9%) | 26 (27.1%) | 163 (29.3%) | 0.663 |
Hematoma location | 0.957 | |||
Unilateral left, n (%) | 288 (44.1%) | 42 (43.8%) | 246 (44.2%) | |
Unilateral right, n (%) | 216 (33.1%) | 31 (32.3%) | 185 (33.2%) | |
Bilateral, n (%) | 149 (22.8%) | 23 (24.0%) | 126 (22.6%) | |
Postoperative bleeding | 136 (20.8%) | 22 (22.9%) | 114 (20.5%) | 0.585 |
GOS at discharge | 0.549 | |||
5, n (%) | 593 (90.8%) | 90 (93.8%) | 503 (90.3%) | |
4, n (%) | 48 (7.4%) | 5 (5.2%) | 43 (7.7%) | |
3, n (%) | 12 (1.8%) | 1 (1.0%) | 11 (2.0%) | |
Preoperative investigation | N = 632 | n = 95 | n = 537 | |
BUN (mmol/L) | 5.3 (4.4,6.5) | 5.9 (4.8,6.9) | 5.2 (4.3,6.4) | 0.001 |